Profile data is unavailable for this security.
About the company
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
- Revenue in USD (TTM)3.62m
- Net income in USD-21.16m
- Incorporated2004
- Employees11.00
- LocationDMK Pharmaceuticals Corp11682 El Camino Real, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 997-2400
- Fax+1 (302) 636-5454
- Websitehttps://www.dmkpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cannabis Global, Inc. | 2.62m | -3.16m | 373.18k | 3.00 | -- | 0.0172 | -- | 0.1425 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
| Life Stem Genetics Inc | 0.00 | -568.02k | 393.34k | 1.00 | -- | 0.21 | -- | -- | -0.013 | -0.013 | 0.00 | 0.0076 | 0.00 | -- | -- | 0.00 | -198.83 | -- | -330.32 | -- | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | -- | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 407.94k | -- | -- | -- | -- | 0.1992 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| Baudax Bio Inc | 310.00k | -25.83m | 435.93k | 9.00 | -- | -- | -- | 1.41 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
| Pharmagreen Biotech Inc | 1.56k | -500.66k | 497.73k | 0.00 | -- | -- | -- | 319.06 | -0.0011 | -0.0011 | 0.00 | -0.0045 | 0.0094 | -- | 3.35 | -- | -302.10 | -472.20 | -- | -- | 11.54 | -- | -32,096.15 | -- | 0.0194 | -71.71 | -- | -- | -- | -- | 80.68 | -- | -- | -- |
| Better Therapeutics Inc | 0.00 | -31.57m | 498.62k | 54.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | -0.2449 | 0.00 | -- | -- | 0.00 | -162.15 | -- | -378.28 | -- | -- | -- | -- | -- | -- | -15.18 | 3.27 | -- | -- | -- | 1.43 | -- | -- | -- |
| DMK Pharmaceuticals Corp | 3.62m | -21.16m | 505.10k | 11.00 | -- | -- | -- | 0.1395 | -8.69 | -9.18 | 1.04 | -0.4918 | 0.3432 | 5.66 | 5.54 | 329,062.70 | -200.59 | -79.00 | -- | -113.05 | -37.30 | 4.85 | -584.50 | -347.59 | 0.5355 | -- | -- | -- | 115.34 | -18.31 | 24.28 | -- | -20.10 | -- |
| Sativus Tech Corp | 0.00 | -324.00k | 523.57k | -- | -- | -- | -- | -- | -0.1091 | -0.1091 | 0.00 | -0.5418 | 0.00 | -- | -- | -- | -45.82 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | -- | -- | 78.78 | -- | -- | -- |
| Hanyuan Biotech International Inc | 10.65m | 3.14m | 539.39k | -- | 0.0294 | 0.0064 | 0.1481 | 0.0506 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Evofem Biosciences Inc | 18.22m | 50.00m | 551.27k | 37.00 | 0.0015 | -- | 0.0109 | 0.0303 | -7.62 | -7.62 | 0.0977 | -3.09 | 1.02 | 1.84 | 5.31 | 492,378.40 | 296.66 | -211.64 | -- | -- | 64.26 | -- | 290.81 | -1,031.55 | 0.1037 | -9.56 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Emo Capital Corp | -100.00bn | -100.00bn | 649.40k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to DMK Pharmaceuticals Corp's reporting currency: US Dollar USD
2.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2023 | 106.21k | 1.05% |
| Tower Research Capital LLCas of 31 Dec 2023 | 65.20k | 0.65% |
| Virtu Americas LLCas of 31 Dec 2023 | 22.19k | 0.22% |
| G1 Execution Services LLCas of 31 Dec 2023 | 20.24k | 0.20% |
| Two Sigma Securities LLCas of 31 Dec 2023 | 18.06k | 0.18% |
| HRT Financial LLCas of 31 Dec 2023 | 16.56k | 0.16% |
| UBS Securities LLCas of 31 Dec 2023 | 1.56k | 0.02% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 365.00 | 0.00% |
| BofA Securities, Inc.as of 31 Dec 2023 | 196.00 | 0.00% |
| Harbour Investments, Inc.as of 31 Dec 2023 | 183.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
